Your browser doesn't support javascript.
loading
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
Haratake, Naoki; Ozawa, Hiroki; Morimoto, Yoshihiro; Yamashita, Nami; Daimon, Tatsuaki; Bhattacharya, Atrayee; Wang, Keyi; Nakashoji, Ayako; Isozaki, Hideko; Shimokawa, Mototsugu; Kikutake, Chie; Suyama, Mikita; Hashinokuchi, Asato; Takada, Kazuki; Takenaka, Tomoyoshi; Yoshizumi, Tomoharu; Mitsudomi, Tetsuya; Hata, Aaron N; Kufe, Donald.
Afiliação
  • Haratake N; Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts.
  • Ozawa H; Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts.
  • Morimoto Y; Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts.
  • Yamashita N; Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts.
  • Daimon T; Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts.
  • Bhattacharya A; Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts.
  • Wang K; Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts.
  • Nakashoji A; Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts.
  • Isozaki H; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Shimokawa M; Department of Biostatistics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.
  • Kikutake C; Division of Bioinformatics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
  • Suyama M; Division of Bioinformatics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
  • Hashinokuchi A; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Takada K; Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
  • Takenaka T; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Yoshizumi T; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Mitsudomi T; Department of Surgery, Kindai University Hospital, Osaka-Sayama, Japan.
  • Hata AN; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Kufe D; Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts. Electronic address: donald_kufe@dfci.harvard.edu.
J Thorac Oncol ; 19(3): 434-450, 2024 Mar.
Article em En | MEDLINE | ID: mdl-37924972
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Acrilamidas / Carcinoma Pulmonar de Células não Pequenas / Indóis / Neoplasias Pulmonares Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Acrilamidas / Carcinoma Pulmonar de Células não Pequenas / Indóis / Neoplasias Pulmonares Idioma: En Ano de publicação: 2024 Tipo de documento: Article